Stokes Capital Advisors LLC Grows Holdings in Novo Nordisk A/S (NYSE:NVO)

Stokes Capital Advisors LLC boosted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 7.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,655 shares of the company’s stock after acquiring an additional 920 shares during the period. Stokes Capital Advisors LLC’s holdings in Novo Nordisk A/S were worth $1,175,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of NVO. Strategic Investment Solutions Inc. IL bought a new stake in shares of Novo Nordisk A/S in the 2nd quarter worth approximately $25,000. Daiwa Securities Group Inc. purchased a new position in Novo Nordisk A/S during the third quarter valued at $28,000. Capital Performance Advisors LLP bought a new stake in Novo Nordisk A/S in the third quarter worth $42,000. Carolina Wealth Advisors LLC purchased a new stake in shares of Novo Nordisk A/S in the third quarter worth $48,000. Finally, M&R Capital Management Inc. increased its holdings in shares of Novo Nordisk A/S by 260.5% during the third quarter. M&R Capital Management Inc. now owns 411 shares of the company’s stock valued at $49,000 after acquiring an additional 297 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Finally, BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Trading Down 5.2 %

NYSE:NVO opened at $78.74 on Monday. The company has a market cap of $353.33 billion, a PE ratio of 25.48, a price-to-earnings-growth ratio of 0.92 and a beta of 0.45. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The company has a 50 day simple moving average of $97.76 and a two-hundred day simple moving average of $117.05. Novo Nordisk A/S has a 12 month low of $78.17 and a 12 month high of $148.15.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.